Trifecta Capital Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Trifecta Capital Advisors’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.1K	Hold	155	–	–	﹤0.01%	250
2025 Q4	$4.49K	Hold	155	–	–	﹤0.01%	243
2025 Q3	$4.3K	Hold	155	–	–	﹤0.01%	275
2025 Q2	$3.77K	Sell	155 -310	-67%	-$6.79K	﹤0.01%	282
2025 Q1	$9.65K	Hold	465	–	–	﹤0.01%	216
2024 Q4	$10.9K	Hold	465	–	–	﹤0.01%	209
2024 Q3	$11.9K	Hold	465	–	–	﹤0.01%	211
2024 Q2	$10.9K	Hold	465	–	–	﹤0.01%	213
2024 Q1	$13.4K	Hold	465	–	–	﹤0.01%	193
2023 Q4	$15.3K	Hold	465	–	–	﹤0.01%	187
2023 Q3	$13K	Hold	465	–	–	﹤0.01%	200
2023 Q2	$15.9K	Hold	465	–	–	0.01%	190
2023 Q1	$14K	Hold	465	–	–	﹤0.01%	200
2022 Q4	$13.1K	Buy	+465	New	+$14.8K	0.01%	183

Other funds holding ARKG

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Trifecta Capital Advisors's ARKG Position: Q1 2026 in Review

Trifecta Capital Advisors held its ARK Genomic Revolution ETF (ARKG) position steady in Q1 2026 at 155 shares worth $4.1K. The position accounts for ﹤0.01% of the portfolio, ranked #250.

Trifecta Capital Advisors first reported a position in ARKG in Q4 2022 and has held it in 14 quarters since. The position peaked at $15.9K in Q2 2023. 218 funds tracked by Wall St. Rank hold ARKG as of Q1 2026.

Trifecta Capital Advisors held 155 shares of ARK Genomic Revolution ETF worth $4.1K as of Q1 2026.
Trifecta Capital Advisors left its ARK Genomic Revolution ETF share count unchanged in Q1 2026.
ARK Genomic Revolution ETF made up ﹤0.01% of Trifecta Capital Advisors's portfolio in Q1 2026, its #250 holding.
Trifecta Capital Advisors first reported a position in ARK Genomic Revolution ETF in Q4 2022 and has held it in 14 quarters since.
Trifecta Capital Advisors's ARK Genomic Revolution ETF position peaked at $15.9K in Q2 2023.
218 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2026.

Based on Trifecta Capital Advisors's 13F filing for Q1 2026, filed 1 May 2026.